# Bevacizumab Versus Ranibizumab for the Treatment of Diabetic Macular Edema

> **NCT01487629** · PHASE2 · UNKNOWN · sponsor: **University of Sao Paulo** · enrollment: 53 (actual)

## Conditions studied

- Diabetic Retinopathy
- Macular Edema

## Interventions

- **DRUG:** Bevacizumab
- **DRUG:** Ranibizumab

## Key facts

- **NCT ID:** NCT01487629
- **Lead sponsor:** University of Sao Paulo
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2010-04
- **Primary completion:** 2012-09
- **Final completion:** 2012-09
- **Target enrollment:** 53 (ACTUAL)
- **Last updated:** 2011-12-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01487629

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01487629, "Bevacizumab Versus Ranibizumab for the Treatment of Diabetic Macular Edema". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01487629. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*